Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis

NCT03926026 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

Blepharitis

Interventions

DRUG: Fluticasone Propionate
DRUG: Placebo

Sponsor

Nicox Ophthalmics, Inc.